Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.

Science

First published in Expert Opinion on Pharmacotherapy on 2014 Jun.
Expert Opin Pharmacother. 2014 Jun;15(9):1299-313. doi: 10.1517/14656566.2014.920009

Authors: Forst T, Bramlage P

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim

LET’S TALK SCIENCE

+49 621 150 45 – 0

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management

LET’S TALK BUSINESS

+49 621 150 45 – 0

Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.